It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBIX’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBIX’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 7 bullish TA indicator(s).
NBIX (@Pharmaceuticals: Other) experienced а -0.80% price change this week, while NTLA (@Biotechnology) price change was +2.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.42%. For the same industry, the average monthly price growth was +14.50%, and the average quarterly price growth was +67.02%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.
NBIX is expected to report earnings on Aug 05, 2025.
NTLA is expected to report earnings on Jul 31, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (-0.75% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
NBIX | NTLA | NBIX / NTLA | |
Capitalization | 13.7B | 861M | 1,591% |
EBITDA | 358M | -530.8M | -67% |
Gain YTD | -8.872 | -28.731 | 31% |
P/E Ratio | 57.20 | N/A | - |
Revenue | 1.89B | 45.6M | 4,138% |
Total Cash | 1.03B | 504M | 205% |
Total Debt | 428M | 119M | 360% |
NBIX | NTLA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 59 | 92 | |
PRICE GROWTH RATING 1..100 | 50 | 65 | |
P/E GROWTH RATING 1..100 | 33 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTLA's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for NBIX (73). This means that NTLA’s stock grew somewhat faster than NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as NTLA (100). This means that NBIX’s stock grew similarly to NTLA’s over the last 12 months.
NBIX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that NBIX’s stock grew somewhat faster than NTLA’s over the last 12 months.
NBIX's Price Growth Rating (50) in the Biotechnology industry is in the same range as NTLA (65). This means that NBIX’s stock grew similarly to NTLA’s over the last 12 months.
NBIX's P/E Growth Rating (33) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that NBIX’s stock grew significantly faster than NTLA’s over the last 12 months.
NBIX | NTLA | |
---|---|---|
RSI ODDS (%) | 5 days ago70% | N/A |
Stochastic ODDS (%) | 1 day ago58% | 1 day ago82% |
Momentum ODDS (%) | 1 day ago71% | 1 day ago80% |
MACD ODDS (%) | 1 day ago69% | 1 day ago74% |
TrendWeek ODDS (%) | 1 day ago62% | 1 day ago79% |
TrendMonth ODDS (%) | 1 day ago71% | 1 day ago90% |
Advances ODDS (%) | 6 days ago72% | 5 days ago77% |
Declines ODDS (%) | 4 days ago62% | 1 day ago88% |
BollingerBands ODDS (%) | N/A | 1 day ago85% |
Aroon ODDS (%) | 1 day ago57% | 1 day ago84% |
1 Day | |||
---|---|---|---|
CRYPTO / NAME | Price $ | Chg $ | Chg % |
BTT.X | 0.000001 | N/A | -1.20% |
BitTorrent [New] cryptocurrency | |||
JUV.X | 1.061050 | -0.019228 | -1.78% |
Juventus Fan Token cryptocurrency | |||
HIGH.X | 0.529171 | -0.012384 | -2.29% |
Highstreet cryptocurrency | |||
COTI.X | 0.052713 | -0.001707 | -3.14% |
COTI cryptocurrency | |||
AGIX.X | 0.307676 | -0.025971 | -7.78% |
SingularityNET cryptocurrency |
A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.
Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
---|---|---|---|---|
NBIX | 100% | -0.50% | ||
LFCR - NBIX | 32% Poorly correlated | -1.46% | ||
EOLS - NBIX | 30% Poorly correlated | -2.46% | ||
CGC - NBIX | 29% Poorly correlated | -3.27% | ||
ELAN - NBIX | 28% Poorly correlated | -2.54% | ||
TLRY - NBIX | 26% Poorly correlated | -2.95% | ||
More |